Search hospitals > British Columbia > VANCOUVER
University of British Columbia
Claim this profileVANCOUVER, British Columbia V6T 1Z4
Global Leader in Alzheimer's Disease
Global Leader in Depression
Conducts research for Depression Treatment
Conducts research for Mild Cognitive Impairment
Conducts research for Stroke
213 reported clinical trials
18 medical researchers
Summary
University of British Columbia is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Alzheimer's Disease, Depression, Depression Treatment, Mild Cognitive Impairment, Stroke and other specialties. University of British Columbia is involved with conducting 213 clinical trials across 414 conditions. There are 18 research doctors associated with this hospital, such as Robin Hsiung, MD, Fidel Vila-Rodriguez, MD, PhD, Andrei Krassioukov, MD,PhD,FRCPC, and Raymond W Lam, MD.Area of expertise
1Alzheimer's Disease
Global LeaderAPP positive
PSEN2 positive
PSEN1 positive
2Depression
Global LeaderTop PIs
Robin Hsiung, MDUBC Hospital7 years of reported clinical research
Studies Alzheimer's Disease
Studies Dementia
10 reported clinical trials
16 drugs studied
Fidel Vila-Rodriguez, MD, PhDUniversity of British Columbia6 years of reported clinical research
Studies Major Depression
Studies Depression Treatment
8 reported clinical trials
13 drugs studied
Andrei Krassioukov, MD,PhD,FRCPCBlusson Spinal Cord Centre2 years of reported clinical research
Studies Spinal Cord Injury
Studies Unintentional Home Injuries
7 reported clinical trials
11 drugs studied
Raymond W Lam, MDUniversity of British Columbia5 years of reported clinical research
Studies Depression
Studies Major Depression
4 reported clinical trials
4 drugs studied
Clinical Trials running at University of British Columbia
Alzheimer's Disease
Dementia
Depression
Prostate Cancer
Major Depressive Disorder
Depression Treatment
Major Depression
Human Papillomavirus
Postoperative Pain
Postoperative Complications
Remternetug
for Alzheimer's Disease
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.
Recruiting0 awards Phase 2 & 32 criteria
Gantenerumab
for Alzheimer's Disease
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Recruiting0 awards Phase 2 & 310 criteria
Disease-Modifying Drugs
for Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Recruiting0 awards Phase 2 & 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of British Columbia?
University of British Columbia is a medical facility located in VANCOUVER, British Columbia. This center is recognized for care of Alzheimer's Disease, Depression, Depression Treatment, Mild Cognitive Impairment, Stroke and other specialties. University of British Columbia is involved with conducting 213 clinical trials across 414 conditions. There are 18 research doctors associated with this hospital, such as Robin Hsiung, MD, Fidel Vila-Rodriguez, MD, PhD, Andrei Krassioukov, MD,PhD,FRCPC, and Raymond W Lam, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.